Skip to main content

Table 3 Multivariate Cox-Proportional Hazard analysis of factors associated with TTP and OS

From: Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

  TTP OS
Variable HR 95% C.I. P HR 95% C.I. P
Type of treatment       
   Vinorelbine 1.0    1.0   
   Docetaxel 0.765 0.538-1.087 0.14 0.474 0.303-0.742 < 0.01
DFI       
   ≥ 21 months 1.0    1.0   
   < 21 months 1.546 1.092-2.189 0.01 1.945 1.249-3.029 < 0.01
Liver involvement       
   No 1.0    1.0   
   Yes 1.568 1.1084-2.268 0.02 1.925 1.186-3.125 < 0.01
Number of involved sites       
   1 1.0   0.01    
   2 1.652 1.071-2.548 0.023 1.568 0.901-2.626 0.12
   ≥ 3 1.999 1.281-3.119 < 0.01 2.004 1.172-3.427 0.01
  1. TTP, time to progression: OS, overall survival: C.I., confidence interval